Company intelligence / Profile preview

Therawis Diagnostics

Munich, Germany

Ownership: Private
Development stage: Other

Overview

Therawis Diagnostics has developed and clinically validated the PITX2 DNA methylation assay as a predictive biomarker for anthracycline-based chemotherapy response in high-risk breast cancer patients. The test demonstrates predictive value in triple-negative and other high-risk breast cancers, addressing the challenge that only 35% of TNBC patients respond to standard anthracycline chemotherapy.

Therapeutic areas: Oncology
Industry: Molecular Diagnostics

Partnerships

QIAGEN

Beyond the preview

Go deeper on Therawis Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therawis Diagnostics.

Explore the full profile